<212> DNA

# PCT/IB2003/005520

### SEQUENCE LISTING

<110>	COLEY PHARMACEUTICAL GROUP LTD COLEY PHARMACEUTICAL GmbH	
<120>	METHODS AND PRODUCTS RELATED TO TREATMENT AND PREVENTION OF HEPATITIS C VIRUS INFECTION	
<130>	C1037.70035US00	
	NOT YET ASSIGNED 2003-10-29	
	US 60/421,987 2002-10-29	
<160>	26	
<170>	PatentIn version 3.2	
<210><211><211><212><213>	21	
<220>		
<223>	Oligonucleotide	-
<400> ggggac	1 gacg tcgtggggg g	21
<210> <211> <212> <213>	24	
<223>	Oligonucleotide	
<400> tcgtcg	2 gtttt gtcgttttgt cgtt	24
<210><211><212><213>	22 DNA	
<220>	$\cdot$	
<223>	Oligonucleotide	
<400> tgctg	3 ctttt tgctggcttt tt	22
<210> <211>		

## WO 2004/039829

2/6

PCT/IB2003/005520

<213>	Artificial sequence		
<220>			
<223>	Oligonucleotide		
<400>	4		
tcgtcgt	ttt eggeggeege eg	22	
<210>	5		
<211>			
<212>			
<213>	Artificial sequence		
<220>	·		
<223>	Oligonucleotide		
<400>	5		
	ttc gtcgttttgt cgtt	24	
.010-			
<210> <211>			
<212>			
	Artificial sequence		
	-		
<220>			
<223>	Oligonucleotide		
-400-			
	6 tttt tegtgegttt tt	22	
205005			
<210> <211>			
<211>			
	Artificial sequence		
	•		
<220>			
<223>	Oligonucleotide		
	· ·		
<400>	7		
tegteg	tttt eggeggeege eg	22	
<210>	8		
<211>			
<212>			
<213>	Artificial sequence		
<220>			
~220>			
<223>	Oligonucleotide		
44.00:			
<400>	8 tttt atcatttat catt	24	
tegtegtttt gtegttttgt egtt 24			

#### PCT/IB2003/005520

<211> <212>	9 22 DNA Artificial sequence	
<220>		
<223>	Oligonucleotide	
<400>	9	22
tegtegt	ttt eggeggeege eg	
<210>	10	
<211>		
<212>		
<213>	Artificial sequence	
<220>		
<223>	Oligonucleotide	
<400>	10	
	tttt eggeggeege eg	22
<210>	11	
<211>	22	
<212>		
<213>	Artificial sequence	
<220>		
<223>	Oligonucleotide	
<400>	11	
tcgtcg	tttt cggcgcgc cg	22
<210>	12	
<211>	22	
<212>	DNA	
<213>	Artificial sequence	
<220>		
<223>	Oligonucleotide	
<400>	12	
tcgtcg	tttt cggcgcgcgc cg	22
<210>	13 ,	
<211>		
<212>		
	Artificial sequence	
<220>		
<223>	Oligonucleotide	

#### WO 2004/039829

<220>

4/6

PCT/IB2003/005520

<400> tcgtcg	13 tttt acggcgccgt gccg	24	
<210><211><211><212><213>	24 DNA		
<220>	•		
<223>	Oligonucleotide		
<400> tcgtcg	14 tttt acggcgccgt gccg	24	
<210>			
<211> <212>			
<213>	Artificial sequence		
<220>	·		
<223>	Oligonucleotide		
<400>		24	
tegteg	tttt acggcgccgt gccg	24	
<210>			
<211> <212>			
	Artificial sequence		
<220>			
<223>	Oligonucleotide		
<400>			
tcgtcg	tttt cggcggccgc cg	22	
<210>			
<211> <212>			
<213>			
<220>	·		
<223>	Oligonucleotide		
<400>			
tegegtegtt eggegegege eg 22			
<210><211><211><212><213>	23		

WO 2004/039829		5/6	PCT/IB2003/005520		
<223>	Oligonucleotide				
<400> 18 togtogacgt toggogogog cog 23					
<210><211><211><212><213>			•		
<220>					
<223>	Oligonucleotide		•		
<400> tcggac	19 gttc ggcgcgcgcc g		21		
	19		-		
<220>	oli zazuslootido				
<223> <400> tcggac	Oligonucleotide 20 gttc ggcgcgccg		19		
<210><211><211><212><213>	20				
<220>	•				
<223>	Oligonucleotide				
<400> tcgcgt	21 egtt eggegegeeg		20		
<210> <211> <212> <213>	20				
<220>					
<223>	Oligonucleotide				
<400> tcgacç	22 gttcg gegegegeeg		20		
<210> <211> <212> <213>	18 DNA				

PCT/IB2003/005520

#### WO 2004/039829

tentnnegnn

6/6

<220> <223> Oligonucleotide <400> 23 18 tcgacgttcg gcgcgccg <210> 24 <211> 18 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide <400> 24 18 tcgcgtcgtt cggcgccg <210> 25 <211> 22 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide <400> 25 22 tcgcgacgtt cggcgcgcgc cg <210> 26 <211> 10 <212> DNA <213> Artificial sequence <220> <223> Oligonucleotide <220> <221> misc\_feature <222> (3)..(3) <223> n is a, c, g, or t <220> <221> misc\_feature (5)..(6) <222> <223> n is selected from GpT, GpG, GpA, or ApA <220> <221> misc\_feature (9)..(10) .<222> <223> n is selected from TpT, CpT, or TpC <400> 26 10